PRESIDENT ENDOCRINE TECHNOLOGY, LLC NY, New York, United States
Abstract Text: Problem: Cancer resistance in colon cancer is linked to over expression of Factor H and its variants (Wilczek Ewa et al. in Int. J. Cancer: 122, 2030–2037 (2008)). The data suggests the inefficiency of immunotherapy with monoclonal antibodies is due to presence of complement immune regulators such as Factor H. Further this resistance can be over come by Factor H Antibody.
Method: We have developed a balanced modulator of Factor H and D to overcome complement mediated immune resistance. Discussions: Overcoming immune resistance and inflammatory cascade of complement over activation will lead to improve immune therapy with current and evolving colon cancer therapies. Further it may also be used for prophylaxis for colon cancer in select subgroup of patients.
